(Q39579131)

English

E-cadherin expression on human carcinoma cell affects trastuzumab-mediated antibody-dependent cellular cytotoxicity through killer cell lectin-like receptor G1 on natural killer cells

scientific article published on May 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

E-cadherin expression on human carcinoma cell affects trastuzumab-mediated antibody-dependent cellular cytotoxicity through killer cell lectin-like receptor G1 on natural killer cells (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

0 references

9

object named as

Atsushi Ochiai

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

2

object named as

Satoshi Fujii

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

4

object named as

Takeshi Kuwata

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

6

object named as

Hirofumi Mukai

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

author name string

Chisako Yamauchi

1

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Taichi Kimura

3

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Noriaki Wada

5

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Naoki Matsumoto

7

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Masashi Fukayama

8

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

language of work or name

0 references

publication date

1 May 2011

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

number of pages

13

1 reference

based on heuristic

inferred from page(s)

International Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

128

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

2125-2137

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25803

21 January 2018

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25803

21 January 2018

Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25803

21 January 2018

New approaches to antibody therapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25803

21 January 2018

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25803

21 January 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25803

21 January 2018

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25803

21 January 2018

Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25803

21 January 2018

Trastuzumab--mechanism of action and use in clinical practice

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25803

21 January 2018

Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25803

21 January 2018

Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25803

21 January 2018

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25803

21 January 2018

Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25803

21 January 2018

Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25803

21 January 2018

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25803

21 January 2018

The multiple roles of PTEN in tumor suppression

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25803

21 January 2018

PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25803

21 January 2018

Proteasome inhibitor bortezomib increases PTEN expression and enhances trastuzumab-induced growth inhibition in trastuzumab-resistant cells.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25803

21 January 2018

Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25803

21 January 2018

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25803

21 January 2018

Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25803

21 January 2018

Overexpression of ErbB2 receptor inhibits IGF-I-induced Shc-MAPK signaling pathway in breast cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25803

21 January 2018

Functions of natural killer cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25803

21 January 2018

Regulation of NK cell responsiveness to achieve self-tolerance and maximal responses to diseased target cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25803

21 January 2018

2F1 antigen, the mouse homolog of the rat "mast cell function-associated antigen", is a lectin-like type II transmembrane receptor expressed by natural killer cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25803

21 January 2018

MAFA-L, an ITIM-containing receptor encoded by the human NK cell gene complex and expressed by basophils and NK cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25803

21 January 2018

Cutting edge: inhibitory functions of the killer cell lectin-like receptor G1 molecule during the activation of mouse NK cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25803

21 January 2018

An unusual inhibitory receptor--the mast cell function-associated antigen (MAFA).

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25803

21 January 2018

Killer cell lectin-like receptor G1 binds three members of the classical cadherin family to inhibit NK cell cytotoxicity

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25803

21 January 2018

Cutting edge: identification of E-cadherin as a ligand for the murine killer cell lectin-like receptor G1.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25803

21 January 2018

KLRG1 binds cadherins and preferentially associates with SHIP-1.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25803

21 January 2018

Tumor-associated E-cadherin mutations affect binding to the killer cell lectin-like receptor G1 in humans

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25803

21 January 2018

Viral and bacterial infections induce expression of multiple NK cell receptors in responding CD8(+) T cells.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25803

21 January 2018

Expansion and contraction of the NK cell compartment in response to murine cytomegalovirus infection

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25803

21 January 2018

Cadherin cell adhesion receptors as a morphogenetic regulator

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25803

21 January 2018

E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25803

21 January 2018

Immunoregulatory functions of KLRG1 cadherin interactions are dependent on forward and reverse signaling

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25803

21 January 2018

Molecular basis for E-cadherin recognition by killer cell lectin-like receptor G1 (KLRG1).

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25803

21 January 2018

Identifiers

10.1002/IJC.25803

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39579131&oldid=1857958348"